SCHEMBL7677110

SCHEMBL7677110

CC(Cn1ccc2cc(F)c(C(F)(F)F)cc21)NC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 8/20 0.42
HTR2A P28223 7/20 0.42
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
HTR2B P41595 1/20 0.39
AAK1 Q2M2I8 3/20 0.36
AR P10275 4/20 0.36
TRPA1 O75762 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRB2 P47870 1/20 0.35
EPHX2 P34913 1/20 0.34
PPARG P37231 1/20 0.34
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
APOBEC3A P31941 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7677108 1.00 HTR2C (0.42) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL7674627 0.86 HTR2C (0.43) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL8904901 0.86 HTR2C (0.56) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL7674622 0.86 HTR2C (0.43) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL7679844 0.78 KMO (0.46) HTR2CHTR2ATRPA1PPARGKDM4E
SCHEMBL7679840 0.78 KMO (0.46) HTR2CHTR2ATRPA1PPARGKDM4E
SCHEMBL8959826 0.77 HTR2C (0.54) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL8959822 0.77 HTR2C (0.54) HTR2CHTR2ACYP1A2CYP3A4CYP2C9
SCHEMBL1435781 0.76 NPY5R (0.42) HTR2CAAK1TRPA1KDM4EALDH1A1
SCHEMBL1435785 0.76 NPY5R (0.42) HTR2CAAK1TRPA1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6380238-B1 FOR THERAPY OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS, AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-30 US disclosed